Edaravone - Mitsubishi Tanabe Pharma

Drug Profile

Edaravone - Mitsubishi Tanabe Pharma

Alternative Names: MCI-186; Norphenazone; Radicava; Radicut; Radicut Bag

Latest Information Update: 25 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Mitsubishi Pharma Corporation
  • Developer Mitsubishi Pharma Corporation; Mitsubishi Tanabe Pharma Corporation
  • Class Neuroprotectants; Pyrazolones; Small molecules
  • Mechanism of Action Free radical scavengers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Amyotrophic lateral sclerosis
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Amyotrophic lateral sclerosis; Cerebral infarction
  • Discontinued Myocardial ischaemia; Parkinson's disease; Reperfusion injury; Stroke; Subarachnoid haemorrhage

Most Recent Events

  • 08 Aug 2017 Launched for Amyotrophic lateral sclerosis in USA (IV)
  • 30 Jun 2017 Mitsubishi Tanabe Pharma expects to launch edaravone for Amyotrophic lateral sclerosis in USA in August 2017
  • 18 May 2017 Updated adverse events and efficacy data from a pivotal phase III trial in Amyotrophic lateral sclerosis released by MT Pharma
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top